Rheumatoid arthritis related interstitial lung disease – improving outcomes over 25 years: a large multicentre UK study

Kelly, C. A. et al. (2021) Rheumatoid arthritis related interstitial lung disease – improving outcomes over 25 years: a large multicentre UK study. Rheumatology, 60(4), pp. 1882-1890. (doi: 10.1093/rheumatology/keaa577) (PMID:33150434)

Full text not currently available from Enlighten.


Objective: This study explores whether the prognosis of interstitial lung disease in rheumatoid arthritis (RA-ILD) has improved over time and assesses the potential influence of drug therapy in a large multicentre UK network. Methods: We analysed data from 18 UK centres on patients meeting criteria for both RA and ILD diagnosed over a 25-year period. Data included age, disease duration, outcome and cause of death. We compared all cause and respiratory mortality between RA controls and RA-ILD patients, assessing the influence of specific drugs on mortality in four quartiles based on year of diagnosis. Results: A total of 290 RA-ILD patients were identified. All cause (respiratory) mortality was increased at 30% (18%) compared with controls 21% (7%) (P =0.02). Overall, prognosis improved over quartiles with median age at death rising from 63 years to 78 years (P =0.01). No effect on mortality was detected as a result of DMARD use in RA-ILD. Relative risk (RR) of death from any cause was increased among patients who had received anti-TNF therapy [2.09 (1.1–4.0)] P =0.03, while RR was lower in those treated with rituximab [0.52(0.1–2.1)] or mycophenolate [0.65 (0.2–2.0)]. Patients receiving rituximab as their first biologic had longer three (92%), five (82%) and seven year (80%) survival than those whose first biologic was an anti-TNF agent (82%, 76% and 64%, respectively) (P =0.037). Discussion: This large retrospective multicentre study demonstrates survival of patients with RA-ILD has improved. This may relate to the increasing use of specific immunosuppressive and biologic agents.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Basu, Professor Neil
Authors: Kelly, C. A., Nisar, M., Arthanari, S., Carty, S., Woodhead, F. A., Price-Forbes, A., Middleton, D., Dempsey, O., Miller, D., Basu, N., Dawson, J., Sathi, N., Ahmad, Y., Palmer, E., Iqbal, K., Janakiraman, G., Koduri, G., and Young, A.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Rheumatology
Publisher:British Society for Rheumatology
ISSN (Online):1462-0332
Published Online:04 November 2020

University Staff: Request a correction | Enlighten Editors: Update this record